Plaza-Menacho showed that RET modulates the sensitivity of ER+ BC to endocrine therapy and that activated RET promotes estrogen-independent activation of ERa, which suggested an interference between RET and the ERa pathway in endocrine-resistant BC (51). Here, RET is linked to breast cancer.